Valuation : Clene Inc.

Market Cap 5.43Cr 4.68Cr 4.39Cr 4.01Cr 7.55Cr 519.44Cr 7.58Cr 52Cr 20Cr 262.21Cr 20Cr 20Cr 869.44Cr P/E 2026 *
-1.64x
P/E 2027 * -2.48x
Enterprise Value 4.97Cr 4.29Cr 4.02Cr 3.67Cr 6.91Cr 475.47Cr 6.93Cr 48Cr 19Cr 240.02Cr 19Cr 18Cr 795.85Cr EV / Sales 2026 *
199x
EV / Sales 2027 * 2.41x
Free-Float
83.03%
Yield 2026 *
-
Yield 2027 * -
1 day-5.37%
1 week-2.08%
Current month-15.65%
1 month-15.23%
3 months-36.87%
6 months-19.04%
Current year-27.94%
1 week 4.17
Extreme 4.17
4.8
1 month 3.96
Extreme 3.955
5.57
Current year 3.88
Extreme 3.88
8.67
1 year 3.88
Extreme 3.88
13.5
3 years 2.28
Extreme 2.2801
15.57
5 years 2.28
Extreme 2.2801
172
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 01/04/2013
Chief Tech/Sci/R&D Officer 67 01/01/2013
Director of Finance/CFO 57 01/02/2022
Director TitleAgeSince
Chairman 65 01/11/2015
Director/Board Member 53 01/09/2019
Director/Board Member 49 01/12/2020
Date Insider Type Main position Quantity % Market Cap.
13/08/26 Free

Founder

3,514 0.0275%
13/08/26 Free

Director

3,514 0.0275%
13/08/26 Free

Director

3,674 0.0288%
Change 5-day change 1-year change 3-year change Capi.($)
-5.37%-2.08%-21.81%-69.64% 5.43Cr
-1.59%-3.35%+64.49%+98.69% 6.95TCr
-1.34%-0.75%+48.56%+90.63% 6.5TCr
-8.37%-12.43%+0.14%-15.42% 2.56TCr
-2.35%-5.75%-12.17%+448.29% 2.59TCr
+0.30%-0.69%+63.18%+11.93% 2.65TCr
-0.96%+10.36%+278.86%+438.78% 2.02TCr
-0.51%+0.23%+33.71%-18.02% 2TCr
-1.91%-4.37%+13.33%+531.29% 1.57TCr
-1.47%+0.68%+43.67%+145.49% 1.35TCr
Average -2.36%-1.94%+51.19%+166.20% 2.82TCr
Weighted average by Cap. -1.93%-1.50%+57.14%+152.78%

Financials

2026 *2027 *
Net sales 2L 2L 2L 2L 3L 2.38Cr 3L 23.91L 9L 1.2Cr 9L 9L 3.99Cr 2.33Cr 2Cr 1.88Cr 1.72Cr 3.23Cr 222.36Cr 3.24Cr 22Cr 8.7Cr 112.25Cr 8.74Cr 8.55Cr 372.19Cr
Net income -3.45Cr -2.97Cr -2.79Cr -2.54Cr -4.79Cr -329.62Cr -4.81Cr -33Cr -13Cr -166.39Cr -13Cr -13Cr -551.72Cr -3.1Cr -2.67Cr -2.5Cr -2.29Cr -4.31Cr -296.27Cr -4.32Cr -30Cr -12Cr -149.55Cr -12Cr -11Cr -495.89Cr
Net Debt -46L -39.64L -37.16L -33.93L -63.91L -44Cr -64.11L -4.41Cr -1.72Cr -22Cr -1.73Cr -1.69Cr -74Cr 18L 15.51L 14.54L 13.28L 25.01L 17Cr 25.09L 1.73Cr 67.32L 8.68Cr 67.58L 66.11L 29Cr
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
-
Date Price Change Volume
28/26/28 $4.230 -5.37% 59,664
27/26/27 $4.470 -3.87% 32,984
26/26/26 $4.650 +4.73% 89,851
25/26/25 $4.440 +0.11% 1,12,100
24/26/24 $4.435 +2.66% 37,313
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.230USD
Average target price
32.20USD
Spread / Average Target
+661.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLNN Stock